Year: 2019
BERGENBIO PRESENTS PRELIMINARY CLINICAL DATA FROM PHASE II COMBINATION TRIAL OF BEMCENTINIB AND LDAC IN ELDERLY AML PATIENTS AT ASH 2019
December 9, 2019
Phase II trial evaluating bemcentinib in combination with low-dose cytarabine (LDAC) in elderly AML patients…
Read More
BERGENBIO ASA: RESULTS FOR THE THIRD QUARTER 2019
November 19, 2019
FDA granted Fast Track Designation for 2L Acute Myeloid Leukaemia (AML)High Impact oral presentation of…
Read MoreBerGenBio to present clinical data from Phase II combination trial of bemcentinib and LDAC trial in elderly AML patients at ASH 2019
November 7, 2019
Bergen, Norway, 7 November 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read MoreBerGenBio’s bemcentinib meets primary endpoint in first cohort of phase 2 NSCLC study in combination with Keytruda ®
November 6, 2019
Primary endpoint, Overall Response Rate, has been met in predominantly PD-L1 negative/low patientsSecondary endpoint, median…
Read MoreBerGenBio Receives FDA Approval of Fast Track Designation for Bemcentinib
October 23, 2019
Bergen, Norway 22nd October 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More
BerGenBio to Present clinical data from Phase II trial with selective AXL inhibitor at 34th Annual SITC Meeting
October 15, 2019
Bergen, Norway, 02 October 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel,…
Read More
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159